Jim Simons Clovis Oncology, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $82,530 - $224,010	-78,600 Reduced 3.43%	2,209,700 $2.63 Million
Q2 2022 Aug 12, 2022	BUY	$0.63 - $2.96 $521,892 - $2.45 Million	828,400 Added 56.74%	2,288,300 $4.12 Million
Q1 2022 May 13, 2022	BUY	$1.43 - $3.14 $1.21 Million - $2.67 Million	849,500 Added 139.17%	1,459,900 $2.95 Million
Q4 2021 Feb 11, 2022	BUY	$2.7 - $4.76 $1.33 Million - $2.35 Million	493,700 Added 423.05%	610,400 $1.65 Million
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $473,801 - $676,860	116,700 New	116,700 $520,000
Q3 2019 Nov 13, 2019	SELL	$3.93 - $15.35 $333,657 - $1.3 Million	-84,900 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$12.81 - $25.67 $1.09 Million - $2.18 Million	84,900 New	84,900 $1.26 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.